Amgen Inc. (formerly Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. Focused on molecular biology and biochemistry, its goal is to provide a healthcare business based on recombinant DNA technology.
| Revenue (TTM) | $38.09B |
| Gross Profit (TTM) | $27.39B |
| EBITDA | $17.27B |
| Operating Margin | 35.50% |
| Return on Equity | 91.50% |
| Return on Assets | 8.67% |
| Revenue/Share (TTM) | $70.68 |
| Book Value | $21.62 |
| Price-to-Book | 20.54 |
| Price-to-Sales (TTM) | 6.21 |
| EV/Revenue | 7.44 |
| EV/EBITDA | 16.08 |
| Quarterly Earnings Growth (YoY) | 64.90% |
| Quarterly Revenue Growth (YoY) | 9.50% |
| Shares Outstanding | $540.63M |
| Float | $539.16M |
| % Insiders | 0.23% |
| % Institutions | 85.14% |
Volatility is currently contracting
Amgen (AMGN) shares sold off after Novartis (NVS) failed to meet its primary endpoint in phase-3 trials. Diane King Hall offers more insight into the volatile moves in the healthcare space.
Zacks spotlights Oportun Financial, Uranium Royalty and Amgen, alongside standout gains from its key stock portfolios.
Phase 3 DeLLphi-305 Study Delivered Highly Significant and Clinically Meaningful Overall Survival Benefit Versus Durvalumab Alone Study Also Met Secondary Progression-Free Survival and Objective Response Rate Endpoints THOUSAND OAKS, Calif., Sept. 8, 2026 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced landmark results from the Phase 3 DeLLphi-305 study, which met its primary endpoint at a pre-specified interim analysis, demonstrating a statistically significant and clinically meaningful improvement in overall survival with IMDELLTRA® (tarlatamab-dlle) in combination with AstraZeneca's Imfinzi® (durvalumab) compared to durvalumab alone.
Big Pharma has been scrambling to restock its pipelines, so a disappointing readout can have a knock-on effect on other drugmakers.
Novartis' pelacarsen failed to reduce cardiovascular events despite lowering the harmful cholesterol Lp(a). The setback raises uncertainty for rival experimental Lp(a) drugs from Amgen and Eli Lilly.
Representative David J. Taylor, a Republican from Ohio, has reported six congressional stock trades, selling off holdings in biotech and technology while purchasing shares in utility, semiconductor, and a regional bank.
Novartis' pelacarsen study failed to cut cardiovascular events, clouding prospects for the drug and highlighting portfolio challenges.
AMGN shares fall as NVS' pelacarsen setback casts investor concern over whether olpasiran can deliver positive phase III outcome data.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Amgen's MariTide could target obesity with less frequent dosing, offering a convenience edge as competition from Lilly and Novo Nordisk intensifies.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on AMGN and any ticker you trade — then tracks every position and per-strategy win rate.
